Scientist - Molecular Validation

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens, including HLA-presented and cell surface antigens, from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.

Through our proprietary EnTiCE® platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors.

Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara Bio Capital, SV Health Investors, and the Francis Crick Institute.

We are seeking a Scientist to join our Molecular Validation team on a fixed-term basis to provide maternity cover and additional laboratory capacity during a period of increased activity and team absences.

The role will support target validation activities across Discovery and Preclinical programmes, with a particular focus on molecular and tissue-based techniques including in situ hybridisation (ISH), immunohistochemistry (IHC), immunofluorescence (IF), support RT-qPCR and related molecular biology approaches. The successful candidate will work closely with scientists across Discovery, Translational Research and Product Pipeline teams to ensure delivery of key programme milestones.

• Perform molecular validation experiments to support target discovery and development programmes.
• Conduct and optimise cell and tissue-based assays including:
  • In situ hybridisation (ISH)
  • Immunohistochemistry (IHC)
  • Immunofluorescence (IF)
• Support RT-qPCR experiments.
• Generate, interpret and communicate high-quality scientific data.
• Support method transfer, documentation and knowledge-sharing activities.
• Troubleshoot assays and contribute to the development of novel experimental approaches.
• Maintain accurate laboratory records in accordance with company procedures.
• Collaborate with cross-functional teams to support Discovery, Preclinical and Translational objectives.
• Contribute to laboratory organisation, equipment maintenance and compliance activities.
• Support external CRO interactions and outsourcing activities where required.

• PhD in Molecular Biology, Cancer Biology, Immunology or a related life science discipline, or equivalent industrial experience.
• Experience performing and troubleshooting tissue-based assays such as ISH, IHC and/or IF.
• Experience working with human tissue samples, FFPE and/or Fresh frozen.
• Familiarity with image analysis software and statistical data analysis.
• Hands‑on laboratory experience in molecular biology techniques.
• Strong data analysis and scientific communication skills.
• Ability to work independently while contributing effectively within a multidisciplinary team.
• Excellent organisational skills and attention to detail.

• Experience in oncology, discovery or translational research.
• Knowledge of biomarker discovery or target validation workflows.
• Experience working with CROs and external collaborators.
• Previous experience in a biotechnology or pharmaceutical environment.

• Collaborative and team oriented.
• Flexible and adaptable in a fast‑paced research environment.
• Proactive problem solver with a strong scientific curiosity.
• Comfortable balancing multiple priorities and changing project needs.
• Committed to high scientific standards and data quality.

• Effective transfer and retention of key Molecular Validation knowledge during maternity leave cover.
• Continued delivery of Discovery and Preclinical programme milestones.
• High‑quality execution of molecular validation assays with minimal supervision.
• Strong partnership with internal stakeholders and effective contribution across multiple projects.

• Applications close on Friday 31 July 2026
  . We review applications on a rolling…